The Epstein-Barr virus transforming protein LMP1 engages signaling proteins for the tumor necrosis factor receptor family.

Department of Medicine, Harvard Medical School, Boston, Massachusetts 02115.
Cell (Impact Factor: 33.12). 03/1995; 80(3):389-99.
Source: PubMed

ABSTRACT The cytoplasmic C-terminus of Epstein-Barr virus (EBV) latent infection membrane protein 1 (LMP1) is essential for B lymphocyte growth transformation and is now shown to interact with a novel human protein (LMP1-associated protein 1 [LAP1]). LAP1 is homologous to a murine protein, tumor necrosis factor receptor-associated factor 2 (TRAF2), implicated in growth signaling from the p80 TNFR. A second novel protein (EBI6), induced by EBV infection, is the human homolog of a second murine TNFR-associated protein (TRAF1). LMP1 expression causes LAP1 and EBI6 to localize to LMP1 clusters in lymphoblast plasma membranes, and LMP1 coimmunoprecipitates with these proteins. LAP1 binds to the p80 TNFR, CD40, and the lymphotoxin-beta receptor, while EBI6 associates with the p80 TNFR. The interaction of LMP1 with these TNFR family-associated proteins is further evidence for their role in signaling and links LMP1-mediated transformation to signal transduction from the TNFR family.

Download full-text


Available from: Mark Birkenbach, Aug 31, 2015
  • Source
    • "LMP1 mimics a constitutively active CD40 receptor (Mosialos et al., 1995). LMP1 constitutively aggregates and recruits TRAFs and TRADD leading to activation of NF-kB, a key transcription factor in viral and nonviral lymphomagenesis (Mosialos et al., 1995). NF-kB promotes cell survival by upregulation of the antiapoptotic proteins A20 and BCL-2 and a variety of cellular genes related to B cell proliferation and malignancy. "
    [Show abstract] [Hide abstract]
    ABSTRACT: Approximately 12% of all human cancers are caused by oncoviruses. Human viral oncogenesis is complex, and only a small percentage of the infected individuals develop cancer, often many years to decades after the initial infection. This reflects the multistep nature of viral oncogenesis, host genetic variability, and the fact that viruses contribute to only a portion of the oncogenic events. In this review, the Hallmarks of Cancer framework of Hanahan and Weinberg (2000 and 2011) is used to dissect the viral, host, and environmental cofactors that contribute to the biology of multistep oncogenesis mediated by established human oncoviruses. The viruses discussed include Epstein-Barr virus (EBV), high-risk human papillomaviruses (HPVs), hepatitis B and C viruses (HBV and HCV, respectively), human T cell lymphotropic virus-1 (HTLV-1), and Kaposi's sarcoma herpesvirus (KSHV).
    Cell host & microbe 03/2014; 15(3):266-282. DOI:10.1016/j.chom.2014.02.011 · 12.19 Impact Factor
  • Source
    • "LMP-1 is considered the major EBV oncoprotein, acting as an oncogene in rodent fibroblast cells [4,5]. LMP-1 functions as a constitutively active tumor necrosis factor receptor, mimicking an activated CD40 receptor, although structurally different [6,7]. LMP-1 has pleiotropic functions being able to promote B-cell activation, homotypic and heterotypic cell adhesion and the expression of cell surface (i.e. "
    [Show abstract] [Hide abstract]
    ABSTRACT: Overcoming cellular senescence is strictly required for virus-driven tumors, including those associated with Epstein-Barr virus (EBV). This critical step is successfully accomplished by EBV through TERT expression and telomerase activation in infected cells. We herein review the complex interplay between EBV and TERT/telomerase in EBV-driven tumorigenesis. Evidence accumulated so far clearly indicates that elucidation of this issue may offer promising opportunities for the design of innovative treatment modalities for EBV-associated malignancies. Indeed, several therapeutic strategies for telomerase inhibition have been developed and are being investigated in clinical trials. In this respect, our recent finding that TERT inhibition sensitizes EBV+ lymphoma cells to antivirals through activation of EBV lytic replication is particularly promising and provides a rationale for the activation of clinical studies aimed at assessing the effects of combination therapies with TERT inhibitors and antivirals for the treatment of EBV-associated malignancies.
    Infectious Agents and Cancer 02/2014; 9(1):8. DOI:10.1186/1750-9378-9-8 · 2.07 Impact Factor
  • Source
    • "LMP1 can transform a variety of cell types, including rodent fibroblasts [169], and is essential for the ability of EBV to immortalize B cells [170]. The multiple transmembrane-spanning domains and the carboxyl terminus of LMP1 can interact with several tumor necrosis factor receptor associated factors (TRAFs) [171, 172]; this interaction results in high levels of activity of NF-jB, Jun, and p38 in LMP1-expressing epithelial and B cells [173–175]. "
    [Show abstract] [Hide abstract]
    ABSTRACT: Oral cancer is one of the most common cancers and it constitutes a major health problem particularly in developing countries. Oral squamous cell carcinoma (OSCC) represents the most frequent of all oral neoplasms. Several risk factors have been well characterized to be associated with OSCC with substantial evidences. The etiology of OSCC is complex and involves many factors. The most clearly defined potential factors are smoking and alcohol, which substantially increase the risk of OSCC. However, despite this clear association, a substantial proportion of patients develop OSCC without exposure to them, emphasizing the role of other risk factors such as genetic susceptibility and oncogenic viruses. Some viruses are strongly associated with OSCC while the association of others is less frequent and may depend on cofactors for their carcinogenic effects. Therefore, the exact role of viruses must be evaluated with care in order to improve the diagnosis and treatment of OSCC. Although a viral association within a subset of OSCC has been shown, the molecular and histopathological characteristics of these tumors have yet to be clearly defined.
    12/2013; 2013:642496. DOI:10.1155/2013/642496
Show more